Søgning på udtrykket 'hepatitis' giver 106 resultater
Dokumenter [11] Sider [4] Kalender [49] Nyt fra tidsskrifterne [+20] Aktuelle smitsomme sygdomme [+20]
Dokumenter [11]
National guideline udarbejdet af en arbejdsgruppe nedsat af medlemmer fra Dansk Selskab for Infektionsmedicin og medlemmer fra Dansk Selskab for Gastroenterologi og Hepatologi.
National guideline udarbejdet af en arbejdsgruppe nedsat af medlemmer fra Dansk Selskab for Infektionsmedicin og medlemmer fra Dansk Selskab for Gastroenterologi og Hepatologi.
Diagnostik, behandling og forebyggelse af infektion med hepatitis A virus (HAV)
Forfattere: Jan Gerstoft, Nina Weis, Terese L. Katzenstein (Dansk Selskab for Infektionsmedicin), Anders Nyboe Andersen og Jens Fedder (Dansk Fertilitetsselskab).
Udarbejdet af en arbejdsgrupper bestående af medlemmer fra Dansk Selskab for Infektionsmedicin og Dansk Transplantationsselskab
Revideret september 2020. Arbejdsgruppen bestod af Suzanne Lunding (formand), Peer Brehm Christensen, Christian Erikstrup, Terese L. Katzenstein, Henrik Krarup, Alex Lund Laursen, Birgitte Mørn og Nina Weis
Program
Program og tilmelding
Ved Andrea Sinclair, SSI
Sider [4]
…At orientere DSI's bestyrelse ved nye medlemmer i gruppen, eller hvis medlemmer udgår efter ønske eller ved inaktivitet., Nedenfor vises selskabets repræsentanter i diverse arbejdsgrupper og udvalg, og publicerede guidelines. Akut viral hepatitis: Carsten Shade Larsen og Nina Weis. Hepatitis A (2013), Antiretroviral terapi: Henrik Nielsen, Jan Gerstoft, Jens Lundgren, Alex Laursen, Niels Obel, Isik Somuncu, Gitte Kronborg, Ann-Brit Eg Hansen Antiviral behandling af…
…ioner: Dato for næste kursus Efterår 2024 (2 dage) : Sted Endnu ikke afklaret Delkursusledelse Jakob Bodilsen og Lars Omland Tidligere kurser 11. og 12. april 2018 9. og 10 september 2021 Gastroenterologiske infektioner og kronisk hepatitis: Dato for næste kursus 4. og 5. december 2023: Sted Odense Universitetshospital Delkursusledelse Lone Mygind, Micha Jepsen og Belinda Mössner Tidligere kurser 3. og 4. december 2020 HIV-infektion: Næste kursus Efterår…
…ogiske oversigter (slides). www.natap.org/. National AIDS Treatment Advocacy Project ? en New York State non-profit NGO ledet af Jules Levin (som selv lever med Hiv og hepatitis). God side, hvis man mangler slides/figurer/tabeller fra studier præsenteret på senest afholdte konferencer kommer ofte med referat (inklusive Jules Levins fortolkning ud fra et patient/aktivist perspektiv). www.clinicaloptions.com/HIV.aspx. Et andet website for opdateringer og sammendrag af konferencer (slides).
Professor Henrik Nielsen kommenterer: I disse år sker et paradigmeskift i behandlingen af kronisk hepatitis C virus infektionen. Mange direkte virkende lægemidler er i afprøvning og med lovende resultater. Snart er interferon-baseret terapi ikke absolut nødvendig, mens oral terapi af kort varighed synes indenfor rækkevidde. Samtidigt er bivirkninger ved de nye lægemidler hidtil beskrevet som milde og sjældne. Kombination af sofosbuvir og ledipasvir i samme tablet bliver muligvis den første effektive…
Professor Nina Weis kommenterer: Kronisk hepatitis B, forårsaget af forekomst af hepatitis B virus i blodet i > 6 måneder, kan klinisk manifestere sig fra asymptomatisk til fibrose, cirrose og hepatocellulært carcinom. Trods forekomst af en effektiv vaccine i mere end 40 år, lever 296 millioner mennesker globalt med kronisk hepatitis B, heraf estimerede 14.500 i Danmark. Aktuelt er eneste behandlingstilbud (ofte livslang) antiviral terapi. Denne artikel gennemgår naturhistorien, kendte og nye biomark…
Kalender [49]
4. december, Odense Universitetshospital
25. september, Hvidovre Hospital
7. juni, Rom, Italien
2. juni, Auditorium 3 og 4, Hvidovre Hospital
26. oktober 2022, Auditorium 3 and 4, Hvidovre Hospital
28. juli 2022, Globalt
17. juni 2022, Auditorium 3+4, Hvidovre Hospital
10. maj 2022, Auditorium 3+4, Hvidovre Hospital
25. marts 2021, Online
3. december 2020, Hvidovre Hospital
28. oktober 2020, Paris, Frankrig
17. september 2020, Auditorium 3-4, Hvidovre Hospital
25. november 2019, Auditorium 3 og 4, Hvidovre Hospital
25. september 2019, London, England
11. september 2019, DGI-byen, København
21. juli 2019, Mexico City, Mexico
22. maj 2019, Rom, Italien
10. maj 2019, Auditorium 3 og 4, Hvidovre Hospital
15. februar 2019, Auditorium, University of Southern Denmark, J. B. Winsløws Vej 25, Odense
24. januar 2019, Aarhus Universitetshospital
11. januar 2019, Aalborg
28. november 2018, Hvidovre Hospital
30. maj 2018, Rom, Italien
4. maj 2018, Hindsgavl, Middelfart
9. april 2018, Amsterdam, Holland
27. februar 2018, Hvidovre Hospital
12. december 2017, Auditorium 3 og 4, Hvidovre Hospital
14. september 2017, IDA Mødecenter, Kalvebod Brygge 31, 1560 København V
30. maj 2017, Hvidovre Hospital
31. januar 2017, Malta
13. oktober 2016, Auditoriet, Syddansk Universitet
25. maj 2016, Rom, Italien
3. juni 2015, Barcelona, Spanien
24. marts 2015, Auditorium 3+4, Hvidovre Hospital
13. november 2014, Auditorium 3-4, Hvidovre Hospital
24. oktober 2014, Rigshospitalet
9. oktober 2014, Frankfurt, Tyskland
18. juli 2014, Aud. 3 og 4, Hvidovre Hospital, Kettegård Allé 30, 2650 Hvidovre
5. juli 2014, Sigtuna, Sverige
23. maj 2014, Aud. 3 og 4, Hvidovre Hospital, Kettegård Allé 30, 2650 Hvidovre
1. maj 2014, Berlin, Tyskland
26. marts 2014, Barcelona, Spanien
30. juni 2013, Kuala Lumpur, Malaysia
20. marts 2013, Rom, Italien
3. marts 2013, Atlanta, Georgia, USA
25. oktober 2012, Danmarks Medie- og Journalisthøjskole
18. oktober 2012, Berlin, Tyskland
7. november 2011, Auditorium 93, Rigshospitalet
24. maj 2011, Rigshospitalet, København
Nyt fra tidsskrifterne [+20]
Der er mere end 20 resultater, måske du vil se flere resultater her?Journal of Infectious Diseases
22.09.2023
AbstractIn November 2021, the U.S. Food and Drug Administration (FDA) reclassified two types of hepatitis C diagnostic tests (HCV antibody and HCV nucleic acid) from Class III to Class II, providing a less burdensome pathway to market for diagnostic companies. This down-classification is anticipated to facilitate innovation in HCV diagnostics, particularly for new point-of-care viral detection assays, and ultimately support HCV elimination efforts by increasing the ease of screening as well as test-and-trea…
Journal of Infectious Diseases
22.09.2023
AbstractGiven the growing HCV epidemic in the U.S., it is imperative to implement a coordinated, equitable public health approach to HCV testing that will facilitate immediate access to treatment, especially for individuals with limited healthcare access and those who inject drugs. Point-of-care (POC) RNA diagnostic tests have the greatest potential to address this need. Future regulatory approval has been facilitated by a recent change in the FDA’s approach to evaluating POC diagnostic tests that have be…
Journal of Infectious Diseases
22.09.2023
AbstractIn 2016, World Health Organization (WHO) introduced global targets for the care and management of hepatitis C virus (HCV) infection to eliminate hepatitis C as a public health threat by 2030. Despite significant improvements in testing and treatment, in 2020 only 23% of all persons infected with HCV globally were diagnosed. We explore examples from global hepatitis C programs in Georgia, Rwanda, and Nigeria that have used decentralized and integrated models to increase access to HCV testing. Georgia…
Journal of Infectious Diseases
22.09.2023
AbstractAn estimated 2.4 million people in the United States are living with hepatitis C virus (HCV) infection. In 2020, the Centers for Disease Control and Prevention updated hepatitis C screening recommendations to test adults aged ≥ 18 years at least once in a lifetime and pregnant persons during each pregnancy. For those with ongoing exposure to HCV, periodic testing is recommended. The recommended testing sequence is to obtain an HCV antibody test and, when positive, perform an HCV RNA test. Examinat…
Journal of Infectious Diseases
22.09.2023
AbstractCurrent HCV prevention efforts and treatment rates must improve for the United States (U.S.) to achieve WHO global elimination targets by 2030[1]. The current multi-day diagnosis and treatment paradigm for hepatitis C (HCV) infection leads to significant loss in the cascade of care, resulting in far fewer patients receiving treatment with direct acting antiviral agents (DAAs) than those diagnosed with HCV infection [2,3]. To achieve HCV elimination, a paradigm shift in access to HCV treatment is nee…
Lancet
22.09.2023
Hepatitis C virus (HCV) is a hepatotropic RNA virus that can cause acute and chronic hepatitis, with progressive liver damage resulting in cirrhosis, decompensated liver disease, and hepatocellular carcinoma. In 2016, WHO called for the elimination of HCV infection as a public health threat by 2030. Despite some progress, an estimated 57 million people were living with HCV infection in 2020, and 300 000 HCV-related deaths occur per year. The development of direct-acting antiviral therapy has revolutionise…
Clinical Infectious Diseases
21.09.2023
AbstractBackgroundWidespread outbreaks of person-to-person transmission of hepatitis A virus (HAV), particularly among people who inject drugs (PWID), continue across the United States and globally. However, the herd immunity threshold and vaccination coverage required to prevent outbreaks is unknown. We aimed to use surveillance data and dynamic modeling to estimate herd immunity thresholds among PWID in 16 U.S. states.MethodsWe used a previously published dynamic transmission model of HAV transmission, ca…
PLoS One Infectious Diseases
21.09.2023
by Yuji Yoshida, Masanori Atsukawa, Chisa Kondo, Michika Kitamura, Kaori Shioda-Koyano, Tadamichi Kawano, Hiroki Ono, Korenobu Hayama, Tomomi Okubo, Taeang Arai, Norio Itokawa, Katsuhiko Iwakiri . Although eliminating HCV can prevent hepatocellular carcinoma (HCC), some patients develop HCC even after obtaining sustained virologic response (SVR). Previously, we developed a new formula to predict advanced liver fibrosis. This study aimed to clarify the usefulness of this formula for predicting HCC after ach…
Virulence
20.09.2023
Volume 14, Issue 1, December 2023 .
Virulence
20.09.2023
Volume 14, Issue 1, December 2023 .
Virulence
20.09.2023
Volume 14, Issue 1, December 2023 .
Virulence
20.09.2023
Volume 14, Issue 1, December 2023 .
Journal of Medical Virology
19.09.2023
Journal of Medical Virology, Volume 95, Issue 9, September 2023.
Journal of Medical Virology
19.09.2023
Journal of Medical Virology, Volume 95, Issue 9, September 2023.
Journal of Medical Virology
19.09.2023
Journal of Medical Virology, Volume 95, Issue 9, September 2023.
Journal of the American Medical Association
6.09.2023
To the Editor We applaud the newly proposed national hepatitis C elimination program that explicitly included justice-involved individuals. Indeed, jails and prisons present an important opportunity for effective intervention; the prevalence of hepatitis C virus in correctional facilities in the US far exceeds estimates in the general population. Persons released from the criminal justice system may account for more than one-third of persons infected with hepatitis C virus in the US.
Journal of the American Medical Association
6.09.2023
To the Editor A recent Viewpoint identified American Indian and Alaska Native persons and non-Hispanic Black persons as groups disproportionately affected by hepatitis C virus. We consider this a problematic classification.
Journal of the American Medical Association
6.09.2023
In Reply We thank Mr Calac and colleagues for highlighting the importance of how race and ethnicity in populations affected by hepatitis C virus are described in a national hepatitis C elimination plan, as described in our recent Viewpoint. National data document that American Indian and Alaska Native and non-Hispanic Black persons are disproportionally affected by hepatitis C. For example, the 2020 Viral Hepatitis Surveillance Report issued by the Centers for Disease Control and Prevention reported that th…
Journal of Medical Virology
5.09.2023
Journal of Medical Virology, Volume 95, Issue 9, September 2023.
Clinical Infectious Diseases
31.08.2023
AbstractBackgroundMany people who have a positive hepatitis C virus (HCV) antibody (Ab) test never receive a confirmatory HCV RNA viral load (VL) test. Reflex VL testing may help address this problem. We undertook a systematic review to evaluate the effectiveness of reflex VL testing compared with standard nonreflex approaches on outcomes across the HCV care cascade.MethodsWe searched 4 databases for studies that examined laboratory-based reflex or clinic-based reflex VL testing approaches, with or without …
Aktuelle smitsomme sygdomme [+20]
Der er mere end 20 resultater, måske du vil se flere resultater her?Eurosurveillance latest updates
22.09.2023
On 5 April 2022, the United Kingdom reported an increase of cases of severe acute hepatitis of unknown aetiology in children, several needing hospitalisation and some required liver transplant or died. Thereafter, 35 countries reported probable cases, almost half of them in Europe. Facing the alert, on 28 April, Portugal created a multidisciplinary Task Force (TF) for rapid detection of probable cases and response. The experts of the TF came from various disciplines: clinicians, laboratory experts, epidemio…
Medscape Infectious Diseases
23.08.2023
Mortality rates remain substantially elevated after successful treatment of hepatitis C infection in the era of interferon-free antiviral therapy, a study of over 20,000 patients has found. . Medscape Medical News
Eurosurveillance latest updates
28.07.2023
. Background. The burden of chronic hepatitis B virus (HBV) varies across the European Union (EU) and European Economic Area (EEA). . . Aim. We aimed to update the 2017 HBV prevalence estimates in EU/EEA countries and the United Kingdom for 2018 to 2021. . . Methods. We undertook a systematic review, adding to HBV prevalence estimates from an existing (2005–2017) database. Databases were searched for original English-language research articles including HBV surface antigen prevalence estimates among t…
Eurosurveillance latest updates
28.07.2023
. Background. Georgia has adopted the World Health Organization European Region’s and global goals to eliminate viral hepatitis. A nationwide serosurvey among adults in 2015 showed 2.9% prevalence for hepatitis B virus (HBV) surface antigen (HBsAg) and 25.9% for antibodies against HBV core antigen (anti-HBc). HBV infection prevalence among children had previously not been assessed. . . Aim. We aimed to assess HBV infection prevalence among children and update estimates for adults in Georgia. . . Metho…
Eurosurveillance latest updates
28.07.2023
. Background. Between May 2015 and February 2022, 77,168 hepatitis C virus (HCV)-infected people in Georgia have been treated through an HCV elimination programme. To project the programme’s long-term impacts, an HCV infection model was initially developed, based on data from surveys among people who inject drugs and a national serosurvey in 2015. . . Aim. Accounting for follow-up surveys in 2021, we validate and update projections of HCV infection prevalence and incidence. . . Method. We assessed the…
Medscape Infectious Diseases
28.07.2023
Managing alcohol-associated hepatitis following hospital discharge requires treating not only the liver disease but also the underlying alcohol use disorder, says a clinical care review. . Medscape Medical News
Morbidity and Mortality Weekly Report (MMWR)
21.07.2023
This report describes progress towards hepatitis B control and elimination in the World Health Organization African region.
Medscape Infectious Diseases
15.07.2023
World Hepatitis Day is an opportunity to remind people of the impact of viral hepatitis and to offer information that can help prevent, diagnose, and treat these diseases, said one expert. . Medscape Medical News
Morbidity and Mortality Weekly Report (MMWR)
14.07.2023
This report describes new CDC guidance for completing hepatitis C virus testing.
Morbidity and Mortality Weekly Report (MMWR)
1.07.2023
This report describes progress towards achieving hepatitis C viral clearance by 2030.
Medscape Infectious Diseases
28.06.2023
Vaccination rates for hepatitis B virus are slightly lower among patients with psoriasis than among people without psoriasis. . Medscape Medical News
Eurosurveillance latest updates
16.06.2023
Echovirus 11 (E11) has recently been associated with a series of nine neonatal cases of severe hepatitis in France. Here, we present severe hepatitis caused by E11 in a pair of twins. In one of the neonates, the clinical picture evolved to fulminant hepatitis. The E11 genome showed 99% nucleotide identity with E11 strains reported in the cases in France. Rapid genome characterisation using next generation sequencing is essential to identify new and more pathogenetic variants.
Morbidity and Mortality Weekly Report (MMWR)
1.06.2023
This report describes the effectiveness of the Cherokee Nation Health Services hepatitis C elimination program after 5 years.
ProMED
27.05.2023
Hepatitis A -- United StatesOnce again, cases of hepatitis A in San Diego County are on the rise with 28 reported to date and 18 among people experiencing homelessness. The county usually reports about 2 virus cases monthly. While no single outbreak location has been identified, and no specific food or water source found, cases are being reported above baseline.The county is doing its part to take steps to prevent more spread of the disease. The current increase in cases is likely due to person-to-person tr…
ProMED
17.05.2023
Hepatitis A -- CanadaVancouver Coastal Health is notifying people who dined at McDonald's (3695 Lougheed Hwy, Vancouver) about a possible exposure to hepatitis A on the following dates and times:19 Apr 2023 - 8am to 4pm21 Apr 2023 - 12pm - 7:30pm23 Apr 2023 - 8am - 4pm26 Apr 2023 - 8am - 4pm27 Apr 2023 - 7am - 2pm28 Apr 2023 - 7am - 3pm29 Apr 2023 - 7am - 3pm30 Apr 2023 - 8am - 4pm2 May 2023 - 7am - 3pm4 May 2023 - 8am - 4pm8 May 2023 - 6am - 11am9 May 2023 - 6am - 9amAlthough the
ProMED
15.05.2023
Hepatitis E -- ChinaHong Kong health officials report investigating a case of human infection of rat Hepatitis E virus (HEV). The case involves a 32-year-old man with underlying illnesses. He was found to have an abnormal liver function during his follow-up in Queen Elizabeth Hospital. The patient is now in stable condition. His blood sample tested positive for rat HEV upon laboratory testing. Epidemiological investigations revealed that the patient resides in Wong Tai Sin. He did not have contact with rode…
ProMED
15.05.2023
Hepatitis A -- CanadaHalton Region Public Health has confirmed a case of hepatitis A at a Milton golf club after a food handler at its restaurant tested positive.The agency says the person worked at RattleSnake Point Golf Club Bistro between 20 Apr 2023 and 2 May 2023. The golf club is working closely with the public health agency to contact affected visitors.Hepatitis A is an infectious disease caused by a virus that attacks the liver. According to the agency, symptoms usually happen within 28 to 30 days
Eurosurveillance latest updates
12.05.2023
. Background. European Union/European Economic Area (EU/EEA) countries annually report hepatitis A (HepA) notifications to The European Surveillance System (TESSy). . . Aim. To describe EU/EEA HepA notifications from 2010 to 2019 and identify infection drivers and surveillance improvements. . . Methods. We analysed demographic, clinical and transmission information of HepA confirmed cases from TESSy. We stratified countries by population susceptibility profile and performed time-series analysis to descr…
ProMED
10.05.2023
Hepatitis A -- United StatesAt a glance-----------Reported cases: 9States: 3Hospitalizations: 3Deaths: 0CDC, state public health and regulatory officials, and the Food and Drug Administration (FDA) are investigating an outbreak of hepatitis A linked to frozen organic strawberries imported from certain farms located in Baja California, Mexico by a common supplier. Frozen organic strawberries may be sold to a variety of retailers under multiple brand labels. Traceback and epidemiological investigations show
ProMED
8.05.2023
Hepatitis E -- South SudanSituation at a glance---------------------On 14 Apr 2023, the Ministry of Health (MoH) of South Sudan declared an outbreak of the hepatitis E Virus (HEV) in Wau city, the capital of Western Bahr el-Ghazal state and one of the largest cities in South Sudan. Between 23 Mar 2023 and 13 Apr 2023, a total of 91 HEV suspected cases have been reported from Wau, of which 35 are confirmed; there have been 5 deaths reported (case fatality ratio [CFR] 5.5%). A multidisciplinary national rapid